R&D channel feed

Months af­ter Re­gen­eron se­cured FDA ap­proval for 12-week Eylea reg­i­men, No­var­tis buys speedy US re­view for its ri­val

7 years ago

Out­rac­ing 2 gi­ant ri­vals, J&J touts promis­ing PhI­II In­vokana da­ta as a game-chang­er for kid­ney dis­ease risks

7 years ago

Al­ny­lam spot­lights just how good the ef­fi­ca­cy da­ta are for givosir­an — tamp­ing down on safe­ty con­cerns

7 years ago
Startups

Clo­vis shut­ters PhII Rubra­ca study af­ter da­ta mon­i­tors turn thumbs down on ef­fi­ca­cy

7 years ago

J&J nabs ac­cel­er­at­ed FDA OK for one of their top late-stage drugs

7 years ago

Go­ing vi­ral? J&J tries to spark a Twit­ter­storm for the lat­est da­ta on its HIV med

7 years ago
Bioregnum
Opinion

A block­buster cock­tail? Gilead slides No­vo Nordisk's semaglu­tide in­to new NASH triple ther­a­py

7 years ago
Pharma

Gilead shores up hope for NASH cock­tail with a glimpse at pos­i­tive proof-of-con­cept da­ta

7 years ago

Bris­tol-My­ers de­tails its fail­ure on Check­mate 451, high­light­ing a bleak fu­ture for their check­point com­bo

7 years ago

Scynex­is finds it­self in the spot­light with a weapon that may fight a su­per­bug that’s scar­ing the world to death

7 years ago

Re­gen­eron, Al­ny­lam spell out a re­search al­liance that could run be­yond a decade, with bil­lions built in for suc­cess

7 years ago
Pharma

Faced by R&D set­backs and ques­tion­able gains, Gilead’s new CEO’s first move is to reach for the ax

7 years ago

FDA, Brigham and Women’s to test if RWE is ripe now for re­plac­ing clin­i­cal drug tri­als

7 years ago
Pharma

BeiGene lines up a next-gen CT­LA-4 to com­ple­ment its PD-1 pil­lar in new deal worth up to $270M

7 years ago
Pharma

Pox­el, part­ner Sum­it­o­mo Dainip­pon taste suc­cess in first piv­otal test for oral di­a­betes drug

7 years ago

Af­ter re­vamp­ing R&D in a glob­al shake­up, Bay­er prep­ping new labs for an ex­pan­sion in can­cer re­search at MIT

7 years ago

FDA snubs Zo­genix's an­ti-seizure drug, not hap­py with some slop­py, in­ad­e­quate R&D work

7 years ago

Unit­ed kills its PhI­II PAH drug af­ter it fails Ty­va­so com­bo study

7 years ago

At a cool $1B-plus in up­front, eq­ui­ty and ear­ly-stage cash, Re­gen­eron ties a block­buster R&D part­ner­ship knot with RNAi leader Al­ny­lam

7 years ago
Pharma

Rat study sug­gests Al­ler­gan's failed an­ti­de­pres­sant ra­pastinel may work as opi­oid ad­dic­tion treat­ment

7 years ago
Discovery

Guard­ing a $2 bil­lion fran­chise op­er­a­tion, Gilead hus­tles up its sN­DA for De­scovy. But will it work?

7 years ago

The point of no re­turn for Mer­ri­mack? Can­cer drug de­vel­op­er ax­es yet an­oth­er drug and more staff

7 years ago

As­traZeneca’s asth­ma drug Fasen­ra looks promis­ing for a set of rare chron­ic im­mune dis­eases

7 years ago

Eye­ing a fast pitch for quick OK in race with blue­bird, J&J/Leg­end team en­joys a reg­u­la­to­ry em­brace for their ri­val BC­MA CAR-T

7 years ago
First page Previous page 248249250251252253254 Next page Last page
A service from the Financial Times